Antidiabetic medication use during pregnancy: an international utilization study

• Published in: BMJ Open Diabetes Research & Care
• Main Authors: Cesta, Carolyn E, Cohen, Jacqueline M, Pazzagli, Laura, Bateman, Brian T, Bröms, Gabriella, Einarsdottir, Kristjana, Furu, Kari, Havard, Alys, Heino, Anna, Hernandez-Diaz, Sonia, Huybrechts, Krista F, Karlstad, Øystein, Kieler, Helle, Li, Jiong, Leinonen, Maarit K, Gulseth, Hanne L, Tran, Duong, Yu, Yongfu, Zoega, Helga, Odsbu, Ingvild
• Other Authors: Læknadeild (HÍ), Faculty of Medicine (UI), Miðstöð í lýðheilsuvísindum (HÍ), The Centre of Public Health Sciences (UI), Heilbrigðisvísindasvið (HÍ), School of Health Sciences (UI), Háskóli Íslands, University of Iceland
• Format: Article in Journal/Newspaper
• Language: English
• Published: BMJ 2019
• Subjects: Drug utilization; Gestational diabetes mellitus; Insulin; Oral antidiabetics; Pharmacoepidemiology; Population-based studies; Pregestational diabetes; Pregnancy; Meðganga; Sykursýki; Lyfjagjöf; Norway; Iceland
• Online Access: https://hdl.handle.net/20.500.11815/1585; https://doi.org/10.1136/bmjdrc-2019-000759

Publisher's version (útgefin grein). Objective Diabetes in pregnancy and consequently the need for treatment with antidiabetic medication (ADM) has become increasingly prevalent. The prevalence and patterns of use of ADM in pregnancy from 2006 onward in seven different countries was assessed. Research design and methods Data sources included individually linked data from the nationwide health registers in Denmark (2006-2016), Finland (2006-2016), Iceland (2006-2012), Norway (2006-2015), Sweden (2006-2015), state-wide administrative and claims data for New South Wales, Australia (2006-2012) and two US insurance databases: Medicaid Analytic eXtract (MAX; 2006-2012, public) and IBM MarketScan (2012-2015, private). The prevalence of ADM use was calculated as the proportion of pregnancies with at least one filled prescription of an ADM in the 90 days before pregnancy or within the three trimesters of pregnancy. Results Prevalence of any ADM use in 5 279 231 pregnancies was 3% (n=147 999) and varied from under 2% (Denmark, Norway, and Sweden) to above 5% (Australia and US). Insulin was the most used ADM, and metformin was the most used oral hypoglycemic agent with increasing use over time in all countries. In 11.4%-62.5% of pregnancies with prepregnancy use, ADM (primarily metformin) was discontinued. When ADM treatment was initiated in late pregnancy for treatment of gestational diabetes mellitus, insulin was most often dispensed, except in the US, where glibenclamide was most often used. Conclusions Prevalence and patterns of use of ADM classes varied between countries and over time. While insulin remained the most common ADM used in pregnancy, metformin use increased significantly over the study period. g This study was funded by NordForsk as part of the Nordic Pregnancy Drug Safety Studies project (Project No: 83539) and the Research Council of Norway as part of the International Pregnancy Drug Safety Studies (InPreSS) (Project No: 273366) both awarded to KF at Norwegian Institute of Public Health (NIHP). ...